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Abstract:  
 
Introduction: Heart failure (HF) guidelines aim to standardise patient care. Internationally, 
prescribing practice in HF may deviate from guidelines and so a standardised tool is 
required to assess prescribing quality. A systematic review and meta-analysis were 
performed to identify a quantitative tool for measuring adherence to HF guidelines and its 
clinical implications. 
 
Methods: Eleven electronic databases were searched to include studies reporting a 
comprehensive tool for measuring adherence to prescribing guidelines in HF patients aged 
≥18 years. Qualitative studies or studies measuring prescription rates alone were excluded. 
Study quality was assessed using the GRACE Checklist.  
 
Results: In total, 2,455 studies were identified. Sixteen eligible full-text articles were 
included (n=14,354 patients, mean age 69±8 years). The Guideline Adherence Index (GAI), 
and its modified versions, was the most frequently cited tool (n=13). Other tools identified 
were: the Individualised Reconciled Evidence Recommendations, the Composite Heart 
Failure Performance, and the Heart Failure Scale. The meta-analysis included the GAI 
studies of good-high quality. The average GAI-3 was 62%. Compared to Low GAI, High 
GAI patients had lower mortality rate (7.6% vs. 33.9%) and lower rehospitalisation rates 
(23.5% vs. 24.5%); both p ≤0.05. High GAI was associated with reduced risk of mortality 
(HR = 0.29, 95% CI 0.06 - 0.51) and rehospitalisation (HR = 0.64, 95% CI 0.41 - 1.00). No 
tool was used to improve prescribing quality. 
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Conclusion: The GAI is the most frequently used tool to assess guideline adherence in HF. 
High GAI is associated with improved HF outcomes.  
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Introduction  
 
Landmark clinical trials (1-3) revealed the benefits of evidence-based therapies on 
mortality, hospitalisation and quality of life in heart failure (HF). However, international 
reports suggest that prescribers do not optimally adhere to the recommendations of HF 
prescribing guidelines(4-6). It has been shown that under-prescribing of evidence-based 
therapies is associated with worsening HF and higher rates of HF hospital admissions and 
mortality (7-9). Furthermore, where these disease-modifying agents are prescribed but at lower 
than target dose, patients may not obtain the full beneficial effect of the agent (5, 10). Thus, HF 
care could be vastly improved with optimal use of guideline-directed therapy (10, 11).  
 
Guideline adherence refers to the adoption of clinical guidelines by clinicians, rather 
than to the patient’s own adherence. There remains a wide variation in HF prescribing 
patterns and quality internationally (5, 12, 13) and several barriers to guideline adherence have 
been described. Prescribing for patients with multiple comorbidities (5), polypharmacy (14), or 
advanced age (14) can affect prescriber’s adherence to guidelines. Furthermore, lack of 
resources in the healthcare setting or lack of knowledge on the behalf of the prescriber may 
also play a role in poor guideline adherence (15).  
 
Given the complexity of HF management, prescription rates alone are not sufficient to 
judge prescribing quality as they do not consider factors such as a patient’s eligibility for or 
contraindication to therapy or achievement of target dose. Innovative methods to measure 
prescription quality in an objective manner and to assess the impact of guideline adherence 
on clinical outcomes are required in order to optimise HF care (14, 15).  
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Therefore, a systematic review and meta-analysis were performed in order to identify 
objective tools for assessing adherence to guideline-led prescribing in HF and to assess the 
clinical outcomes associated with guideline adherence measured by such tools.  
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Methods  
 
 
Search Strategy  
 
The systematic review was performed in line with Preferred Reporting Items for 
Systematic Review and Meta-Analyses (PRISMA) guidelines (16). A database search was 
performed and duplicate results were removed. Two reviewers (SE, MB) independently 
reviewed the titles and abstracts of studies identified in the search. Studies that were eligible 
for full-text review were identified and reviewed by the two reviewers (SE, MB) for final 
determination of study inclusion in the systematic review and meta-analysis. 
 
 
Information Sources  
 
The following electronic databases were searched in April 2016: Medline PubMed, 
Scopus, Web of Knowledge, Science Direct, CINAHL, PsycInfo, EMBASE, Cochrane 
Library, Campbell Collaboration, Open Grey and Grey Lit. No restriction was placed on 
publication date or language.  
 
 
Search method  
 
The following search terms were combined as appropriate across each database: 
heart failure, care indicator, global prescribing score, guideline adherence indicator, 
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guideline adherence index, GAI, guideline compliance, guideline implementation, 
implementation of guidelines, process indicator, quality circle, strategies for guideline 
implementation, underutilisation of evidence-based therapies in heart failure. The search 
terms were used as single terms or combined via Boolean logic (AND, OR) in each of the 
aforementioned databases. 
 
 
Eligibility criteria 
 
The inclusion criteria for the systematic review were studies (i) specific to chronic or 
acute HF patients aged ≥18 years, (ii) measuring adherence to a national or international 
chronic or acute HF guideline; (iii) using a quantitative tool to assess adherence to 
prescribing guidelines. The exclusion criteria for this systematic review were (i) studies 
reporting drug utilisation rates in the absence of a quantitative or comprehensive tool and (ii) 
qualitative studies. Risk of bias assessment was performed using the Good ReseArch for 
Comparative Effectiveness (GRACE) Checklist for observational studies (17). 
 
 
Meta-analysis 
 
A meta-analysis was performed on studies identified in the systematic review that 
used the Guideline Adherence Index (GAI) tool to assess guideline adherence. Studies of 
good to high quality according to the GRACE Checklist were included in the meta-analysis. 
The following GAI-based measures (18) were reported in the meta-analysis: i) overall GAI is a 
mean score of the guideline adherence levels (range from 0% - 100%) of all the eligible 
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patients prescribed HF medications as recommended by the relevant guideline; ii) GAI-3 is 
the proportion of eligible patients prescribed the three principle HF disease-modifying 
therapies: renin-angiotensin system inhibitor (RASi), beta-blocker and mineralocorticoid 
receptor antagonist (MRA) according to the indications of the relevant guideline; iii) GAI-5 
is the proportion of eligible patients prescribed the recommended five standard HF 
medications: RASi, beta-blocker, MRA, loop diuretic and cardiac glycoside according to the 
indications of the relevant guideline. Furthermore, GAI score could be reported as tertiles (18): 
(a) Perfect GAI is prescription of the three principle HF medications; (b) Medium GAI is 
prescription of two out of the three HF medications; c) Poor GAI is prescription of one or 
zero HF medications. However, in this study, GAI scores are categorised into dichotomous 
levels only (i) High GAI that is prescription of ≥2 recommended HF agents and (ii) Low GAI 
that is prescription of <2 recommended HF agents. GAI could also be calculated for each 
pharmacological substance class individually as the proportion of eligible patients to the 
proper pharmacological substance class. This is usually compared to the drug utilisation rate 
(DUR) that is the percentage of patients prescribed a medication out of the total population 
regardless of the patient’s eligibility.  
 
 
Meta-analysis of patient outcomes associated with guideline adherence 
 
Data were extracted from the studies identified using a structured form in Microsoft 
Office Excel® 2016. Pooled odd ratios (OR) and respective 95% confidence intervals (CIs) 
were displayed using the forest plot generator of DistillerSR®. Hazard ratios (HR) and 
respective 95% CIs were pooled using NCSS® Statistical Software for Data Analysis v11 for 
meta-analysis of HRs, computed by random effects regression for combining study data. 
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Cochran’s Q test was used to estimate heterogeneity. Random effects are applied to 
compensate for the potential for between-study heterogeneity in observational studies. Means 
were rarely reported with an estimate of variability, and consequently, presented as pooled 
mean with its appropriate standard deviation or the range of means. 
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Results 
 
 
Search Results  
 
A total of 2,454 titles were identified through the database search and one manuscript 
via hand search. Of these, 1,529 were duplicates. Following title and abstract review 66 
studies were identified as eligible for full-text review. Finally, 16 studies were considered as 
relevant to this systematic review as shown in PRISMA flowchart (Figure 1).  
 
 
Profile of included studies 
 
The characteristics of each included study are shown in Table 1. All included studies 
were non-interventional. Study populations ranged from 58 – 3,292 HF patients. The 
combined study population included in the review was 14,354 HF patients and the mean age 
was 69.0±8.0 years. Patients having HF with reduced ejection fraction (HFrEF) were included 
in all 16 studies and patients having HF with preserved ejection fraction (HFpEF) in 11 
studies (18-28). The studies reported the use of guideline adherence assessment tools in several 
different healthcare settings including eight studies performed in ambulatory care (18, 19, 21, 24, 
25, 29-31), six studies in primary care (23, 27, 28, 30, 32, 33) and seven studies in hospital inpatient 
settings (19, 20, 22, 26, 29, 31, 33). Seven studies (18, 21, 25, 26, 29-31) included a follow-up period of 6-12 
months while two studies (19, 20) reported a follow-up period of almost two years. Twelve 
studies were performed in Europe, six of which were performed in Germany (18, 19, 21, 27, 29, 32). 
All studies assessed guideline adherence by reference to European Society of Cardiology 
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(ESC) guidelines except Popescu et al. (20) which used an American quality measure. Fifteen 
studies were adjudged to be of good - high quality (Table 1). One study was judged to be of 
poor quality and was not included in the meta-analysis (31).  
 
 
Tools identified in the systematic review 
 
Four objective tools were identified in this review: i) the GAI (18); ii) the Composite 
Heart Failure Performance (20); iii) the Heart Failure Scale (23) and iv) the Individualized 
Recommended Evidence-based Reconciliation (IRER) (24).  
 
The GAI (18) is defined as the proportion of eligible HF patients who are prescribed 
guideline-directed therapy by their physician according to the indications of 2001 European  
HF guidelines (34). Thirteen of the 16 studies identified used the GAI (18, 19, 21, 22, 25-33). This tool 
has been modified in several ways since its publication and only two studies used the original 
tool (28, 30). Modifications to the GAI include the consideration of contraindications to therapy 
(19, 22, 25, 28, 29, 32, 33), recommended target doses (25, 32), general practitioner rationale (27, 33) and 
patients’ socioeconomic level (22, 33) as eligibility criteria for guideline adherence.  
 
Each of the other guideline adherence tools identified has been reported in a single 
study. The Composite Heart Failure Performance (20) is calculated as a ratio of the number of 
HF patients in a given hospital who received guideline-directed treatment divided by the 
number of HF patients in that hospital who should have received the indicated treatment. 
Therefore, this tool was developed for application at a hospital population level rather than at 
a direct patient level. The third tool identified is the Heart Failure Scale (23). It is calculated as 
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the percentage of HF patients appropriately receiving the following elements of care: 
laboratory tests, lipid profile, prescription of a RASi and prescription of a beta-blocker. The 
fourth tool is the Individualized Recommended Evidence-based Reconciliation (IRER) (24). 
This tool consists of software that merges the guidelines of several chronic diseases and 
includes recommendations on vaccination, lifestyle measures and therapy goals as well as 
pharmacological therapy. The software generates a list of evidence-based recommendations 
personalised to each HF patient. This is the most recently published tool and is characterised 
by its multi-disciplinary approach, however it does not take contraindications to therapy into 
consideration. All non-GAI studies took into account some clinical aspects of prescribing 
such as availability of echocardiography results or serum creatinine level as a pre-requisite to 
RASi prescription. The components of clinical care considered by each tool are described in 
Supplemental Material Table S1.  
 
No tool identified here has been utilised as a tool to improve or to optimise the quality 
of prescribing in HF patients. Furthermore, no tool assessed the management of acute HF.  
 
Measured guideline adherence and changes in guideline adherence indices over time  
 
The studies reporting the IRER and the Composite Heart Failure Performance both 
reported guideline adherence of >90% whereas the Heart Failure Scale reported a relatively 
low guideline adherence score of 1.6 / 4. Among studies reporting GAI, the mean GAI-3 was 
62.9% ± 20.4% (range 14% - 95%) in the time period from 2005 to 2016. These changes 
reflect the on-going modifications to the GAI and guideline updates. Also, small sample size 
may adversely affect overall GAI score in certain studies such as Oliveira et al. (22).   
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Guideline adherence tools compared to drug utilisation rates  
 
 Four GAI based studies reported DUR and GAI scores for RASi, beta-blockers and 
MRAs (Supplemental Material Table S2). Two studies (18, 22) showed that GAI scores of 
pharmacological classes were higher than DUR scores as GAI consider patient’s eligibility to 
therapy as denominator. However, the other two studies (28, 32) showed the opposite result. 
This paradox was explained by Klimm et al. (32), as GAI score should take into account both 
contraindications and achievement of target dose in order to reflect the guideline’s 
recommendations comprehensively. However, in Bosch et al.(28), the higher DURs were 
justified as HF medications were prescribed to patients in absence of their indications. 
 
Daily target dose prescription 
 
Six studies (25-28, 32, 33) reported the frequency of HF patients receiving >50% of the 
daily target dose of disease-modifying therapy (Figure 2). Overall, 45.5% of patients were 
prescribed >50% of target dose of RASi and 33.2% of patients were prescribed >50% of 
target dose of beta-blocker. The daily dose of MRAs was studied in two populations (26, 33) 
where >50% daily target dose was prescribed to 95.6% and 100% of patients respectively.   
 
Guideline adherence achieved by cardiologists and general practitioners 
 
Three studies compared general practitioner (GP) and cardiologist prescribing 
patterns. Stork et al.(19) calculated the GAI-3 as 67% for cardiologists and 60% for GPs (p-
value= 0.01). Luttick et al.(30) calculated the GAI for each type of prescriber at baseline and at 
one-year follow-up. The GAI rates for GP prescribers were 95% at baseline and 92% at 
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follow-up and the GAI rates for cardiologists were 94.5% at baseline and 91% at follow-up. 
However, the difference at both time points was non-significant. Elsewhere, Bosch et al. (28) 
found that the percentage of patients receiving the guideline-directed target dose of ACE-
inhibitors was significantly higher when prescribed by a cardiologist than when prescribed by 
a GP (29.5% vs. 14.3%, p-value <0.05). Elsewhere, Visca and colleagues (23) found that 
single or team-based GP practice has no relationship with the HF composite score.  
 
Achievement of High Guideline Adherence Index  
 
High GAI achievement was calculated in eight GAI studies (18, 19, 21, 25-27, 29, 32). The 
mean proportion of patients achieving High GAI was 53.8±12.2% (range 38% (19) to 71% (26, 
29)). Before 2010, mean proportion of HF patients achieving High GAI was 42.5% while in 
the period since 2010, a mean of 63% of patients have achieved High GAI. Clinical associates 
of High GAI achievement are illustrated in Figure 3. 
 
Clinical outcomes associated with Guideline Adherence Index 
 
The clinical impact of guideline adherence was studied in seven study populations (18, 19, 21, 25, 
26, 29, 30). Two studies (21, 29) reported Cox proportional hazards models estimating the 
relationship between GAI and one-year mortality. Mortality risk associated with High GAI 
ranged from 5% to 13% while mortality risk associated with Low GAI ranged from 10% to 
21.5% (Log-rank p-value <0.005 each). On the other hand, six studies (18, 19, 21, 22, 25, 26) 
reported mortality rates as mortality percentage in the whole population sample, High GAI 
and Low GAI cohorts separately as 16.0±8.1%, 7.6±3.0% and 33.9±18.8% respectively. Both 
approaches of mortality outcome measurement showed a significant mortality benefit of High 
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GAI levels over Low GAI levels. Adjusted for age and sex, High GAI score was a significant 
independent predictor of mortality risk reduction in five studies (overall HR = 0.289, 95% 
CI= 0.061 - 0.516, Figure 4).  
 
 All-cause hospital admission was studied in three populations (18, 25, 30) where the 
overall mean rehospitalisation rate was 9.1±6.1%. In addition, the variation of 
rehospitalisation rates among the different GAI cohorts was studied in two study populations 
(18, 29), where the overall mean rehospitalisation rate per 100 patients in the High GAI cohorts 
was 23.5±20.2% but in the Low GAI cohorts was 24.23±10.6%. Paradoxically, Zugck et 
al.(29) reported that HF hospitalisation rate was significantly higher in the High GAI cohort 
than in the Low GAI cohort (50% vs. 36%, p-value= 0.026) although a clear explanation for 
this effect was not offered. Finally, in the MAHLER study over a 12-month follow-up period, 
risk of rehospitalisation was significantly reduced in patients with High GAI compared to 
those with Low GAI (HR = 0.64, 95% CI 0.41 - 1.00).  
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Discussion  
 
 The current review is the first to assess the evidence regarding standardised 
quantitative tools for assessment of guideline-led prescribing in HF. It is a rigorous study of 
guideline adherence measurement and its potential to improve patient outcomes. Four 
quantitative tools were identified from 16 studies, each a comprehensive approach for 
assessment of prescription of evidenced-based HF therapies. The reviewed studies 
encompassed different healthcare settings and different prescriber types. Furthermore, several 
studies reported the effect of guideline adherence on clinical outcomes.  
 
 Of the four tools identified for assessing guideline adherence, the GAI was the most 
frequently cited, and was used predominately in Europe. The GAI only accounts for patients 
who are eligible for a particular therapy, according to the guideline indications. This is a more 
accurate assessment of prescribing than simple drug utilisation rates. Moreover, the GAI has 
been modified to keep pace with on-going guideline changes. The Heart Failure Composite 
Score and the Heart Failure Scale each considered just two HF medications – RASi and beta-
blockers - as these are the therapies with the strongest evidence-base. However, both of these 
tools included aspects of laboratory or diagnostic medical tests that are not taken into account 
by the GAI such as examining echocardiographic evidence or serum creatinine levels before 
prescribing an ACE inhibitor. The IRER is the most recently described tool and is the only 
tool reviewed here that was developed for electronic use. This tool merges guideline 
recommendations for HF and for common HF comorbidities such as chronic obstructive 
pulmonary disease, dyslipidaemia and atrial fibrillation, in a single list for each patient. 
However, it does not take into account the patient’s eligibility or any contraindication to HF 
drug therapy.   
  18 
 
 The GAI was originally developed by Komajda and colleagues (18) in 2005 as a means 
to quantify prescribing quality for HF patients in Europe. However, this original GAI has 
some limitations. That is why Stork et al. and Klimm et al.(19, 32) modified the GAI to include 
target dose and contraindications to therapy. Bosch et al. (28) and Deticek et al. (26) considered 
the issue of HF licenced medications as part of guideline adherence although Deticek’s study 
did not illustrate the method of GAI calculation clearly.   
 
Most recently, Hirt et al. (27) and Oertle et al. (33) included a qualitative aspect in their 
GAI studies and showed that GAI is significantly higher when quantitative as well as 
qualitative patient data are considered. This supports previous data showing that patient and 
prescriber factors may be important barriers to guideline adherence (15). These barriers 
included complexity of treatment in the elderly, patient’s multiple comorbidities or low socio-
economic status. However, these barriers were different to those barriers identified in the 
SHAPE study (13). The latter emphasised the prescriber lack of knowledge and education as 
significant contributors to guideline non-adherence.  
 
Although the mean overall GAI score was moderate, fluctuation in GAI scores might 
be influenced by the changing definitions of GAI (18, 32) or due to the wide variation in clinical 
practice between countries (5, 13). This moderate GAI score demonstrates that there is great 
scope for optimising HF prescribing internationally. In the work reported here, guideline 
adherence by cardiologists was similar to that of GPs. The rates reported for both types of 
prescriber in this review are considerably greater than those reported in the 2008 NEHI report 
(35), that showed guidelines adherence of 70% for cardiologists and 47% for GPs in cardiac 
disease management in the United States. The higher guideline adherence rates reported in 
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this review may indicate greater dissemination and acceptability of HF guidelines and 
diminishing barriers to guideline adherence in Europe in the intervening period. The 
increasing proportion of High GAI rates reported from 2005 to 2016 supports this. However, 
there is still room for optimising target dose prescribing as the combined levels of target dose 
achievement in this review were lower than those reported recently by Barywani et al. 
(10).  No study examined the role of the GAI in initiatives to improve guideline adherence or 
how pharmacists or other members of the healthcare team may implement the GAI. 
 
Optimal use of guideline-directed therapy significantly improves HF care. This review 
reveals a positive relationship between High GAI and beneficial clinical outcomes albeit in a 
small number of observational studies. This finding is in line with other studies in the 
literature which show that the beneficial impact of higher levels of guideline adherence (7, 8). 
  
 
Conclusion 
  
Several tools have been developed to measure guideline adherence in HF. The GAI and its 
respective modifications represent a comprehensive and practical approach for assessment of 
guideline-led prescribing in HF. The GAI offers a reliable quantitative tool when compared to 
DURs. Future work may focus on using the modified GAI as a tool to improve prescribing 
quality. 
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Table 1.  Profile and characteristics of the studies included in the systematic review. 
Study author, 
country, year 
Study design Study aim Sample 
number 
Mean 
age 
(years) 
Guideline 
Assessed 
Assessment 
Tool 
Equation / 
Modifications 
Main outcomes 
of tool 
Quality 
Komajda, 
France, Italy, 
Netherlands, 
Spain, 
Germany, 
United 
Kingdom 
2005 (18) 
Prospective, 
observational, 
multicentre 
study in 
ambulatory 
care settings. 
Clinical impact 
of guideline 
adherence on 
hospitalisation 
and time to 
hospitalisation 
1,410 68.6 European 
Society of 
Cardiology 
2001 
GAI (Medications 
indicated / 
Total 
medications 
prescribed) 
x100 
GAI-3 = 60% 
GAI-5 = 63% 
Good 
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Study author, 
country, year 
Study design Study aim Sample 
number 
Mean 
age 
(years) 
Guideline 
Assessed 
Assessment 
Tool 
Equation / 
Modifications 
Main outcomes 
of tool 
Quality 
Stork, 
Germany 
2008 (19) 
Prospective, 
observational, 
multicentre 
study in 
hospitals and 
ambulatory 
care settings. 
Determinants 
of guideline 
adherence 
1,054 72.6 European 
Society of 
Cardiology 
2001 
GAI Consider 
contraindicatio
ns 
HFrEF GAI-3 = 
67% 
HFrEF GAI-5 = 
75% 
High HFrEF 
GAI-5 = 47% 
High 
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Study author, 
country, year 
Study design Study aim Sample 
number 
Mean 
age 
(years) 
Guideline 
Assessed 
Assessment 
Tool 
Equation / 
Modifications 
Main outcomes 
of tool 
Quality 
Klimm, 
Germany 
2008 (32) 
Prospective, 
observational, 
multicentre 
study in 
primary care 
units. 
Assessment of 
guideline 
adherence among 
general 
practitioners 
167 68.2 German 
guidelines 
2005 
GAI Consider 
contraindicatio
ns and target 
dose 
GAI-3 = 25%, 
mGAI-3 = 16% 
Target dose 
RASi = 16% 
Target dose 
beta blocker = 
8% 
Perfect GAI = 
44% 
High 
  27 
Study author, 
country, year 
Study design Study aim Sample 
number 
Mean 
age 
(years) 
Guideline 
Assessed 
Assessment 
Tool 
Equation / 
Modifications 
Main outcomes 
of tool 
Quality 
Popescu, 
USA 
2008 (20) 
Retrospective, 
observational, 
multicentre 
study in 
hospitals 
Assess hospital 
compliance with 
quality measures 
N/A N/A Centre for 
Medicare 
and 
Medicaid 
Services 
performan
ce 
measures 
Composite 
Heart 
Failure 
Performanc
e 
(Number of 
patients 
prescribed 
ACE inhibitor 
/ Number of 
ACE inhibitor 
candidates) x 
100 
Performance 
rate = 90.9% 
High 
  28 
Study author, 
country, year 
Study design Study aim Sample 
number 
Mean 
age 
(years) 
Guideline 
Assessed 
Assessment 
Tool 
Equation / 
Modifications 
Main outcomes 
of tool 
Quality 
Bosch, 
Netherlands 
2010 (28) 
Prospective, 
observational 
multicentre 
study in 
primary care 
Evaluation of 
heart failure 
treatment in 
Dutch primary 
care 
357 75.7 European 
Society of 
Cardiology 
2005 
GAI None GAI-3 = 53.3% 
RASi target 
dose = 48.8% 
Beta blocker 
target dose = 
12% 
RASi + beta 
blocker + MRA 
= 10.4% 
High 
  29 
Study author, 
country, year 
Study design Study aim Sample 
number 
Mean 
age 
(years) 
Guideline 
Assessed 
Assessment 
Tool 
Equation / 
Modifications 
Main outcomes 
of tool 
Quality 
Frankenstein, 
Germany 
2010 (21) 
Prospective, 
observational, 
multicentre 
study in 
ambulatory 
care settings 
Assessment of 
impact of 
guideline 
adherence on 
survival 
3,292 60.75 European 
Society of 
Cardiology 
2005 
GAI Consider 
contraindicatio
ns; relative 
GAI 
Crude GAI = 
47.9% (1994- 
2000) 
Crude GAI = 
70.8% (2001-
2007) 
Relative GAI-3 
improved from 
66% (2000) – 
100% (2007) 
High 
  30 
Study author, 
country, year 
Study design Study aim Sample 
number 
Mean 
age 
(years) 
Guideline 
Assessed 
Assessment 
Tool 
Equation / 
Modifications 
Main outcomes 
of tool 
Quality 
Oertle, 
Switzerland 
2010 (33) 
Retrospective, 
observational 
single-centre 
study in 
hospital 
setting 
Understanding 
the suboptimal 
utilisation of 
evidence based 
medicine in heart 
failure 
348 81.5 European 
Society of 
Cardiology 
2005 
GAI Corrected for 
chronic kidney 
disease and 
adjusted by 
general 
practitioners’ 
rational 
GAI-3 = 70%, 
GAI-5 = 60% 
Corrected GAI-
5c = 80% 
Adjusted GAI-
5a = 90% 
Good 
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Study author, 
country, year 
Study design Study aim Sample 
number 
Mean 
age 
(years) 
Guideline 
Assessed 
Assessment 
Tool 
Equation / 
Modifications 
Main outcomes 
of tool 
Quality 
Zugck, 
Germany 
2012 (29) 
Retrospective, 
observational, 
multicentre 
study in 
various 
medical 
settings 
Evaluation of 
guideline 
adherence level 
and its 
determinants 
2,682 65.5 European 
Society of 
Cardiology 
2005 
GAI Consider 
contraindicatio
ns 
Perfect GAI = 
71.1% 
Moderate GAI 
= 22.4% 
Poor GAI = 
6.5% 
Good 
  
  32 
Study author, 
country, year 
Study design Study aim Sample 
number 
Mean 
age 
(years) 
Guideline 
Assessed 
Assessment 
Tool 
Equation / 
Modifications 
Main outcomes 
of tool 
Quality 
Visca, 
Italy 
2013 (23) 
Retrospective, 
observational, 
multicentre in 
primary care 
units 
Assess impact of 
team practice in 
family medicine 
1,962,1
37 
admissi
ons 
54.3 New 
Zealand 
guidelines 
2009 & 
other 
internation
al 
guidelines 
Heart 
Failure 
Composite 
Scale 
Scale of four 
evidence based 
criteria (Serum 
creatinine + 
lipid levels + 
ACE inhibitor 
+ beta blocker) 
Heart Failure 
Composite 
Scale = 1.64/4 
High 
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Study author, 
country, year 
Study design Study aim Sample 
number 
Mean 
age 
(years) 
Guideline 
Assessed 
Assessment 
Tool 
Equation / 
Modifications 
Main outcomes 
of tool 
Quality 
Oliveira, 
Brazil 
2013 (22) 
Prospective, 
observational 
single-centre 
hospital 
Evaluation of 
physician 
guideline 
adherence 
53 57.1 Brazilian 
guidelines 
2009 
GAI Consider 
contraindicatio
ns 
GAI-3 = 40.7% Good 
Poezl, 
Austria 
2014 (25) 
Multi-centre 
in ambulatory 
care settings 
Study of 
guideline 
adherence and 
dose effect 
2,824 65.0 European 
Society of 
Cardiology 
2012 
GAI Consider target 
dose 
GAI = 75.7% 
Improved 
target dose 
based GAI = 
64.4% 
High 
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Study author, 
country, year 
Study design Study aim Sample 
number 
Mean 
age 
(years) 
Guideline 
Assessed 
Assessment 
Tool 
Equation / 
Modifications 
Main outcomes 
of tool 
Quality 
Yoo, 
Korea 
2014 (31) 
Retrospective, 
observational, 
multicentre 
study, hospital 
settings 
Guideline 
adherence 
assessment and 
its outcomes 
1,319 69.0 European 
Society of 
Cardiology 
2008 
GAI None GAI-0 = 1.5% 
GAI-3 = 43.6% 
Good GAI = 
82% 
Poor 
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Study author, 
country, year 
Study design Study aim Sample 
number 
Mean 
age 
(years) 
Guideline 
Assessed 
Assessme
nt Tool 
Equation / 
Modifications 
Main outcomes of 
tool 
Quality 
Luttik, 
Netherlands 
2014 (30) 
Prospective, 
observational, 
multicentre 
study in 
primary care 
units 
Assessment of 
guideline 
adherence in 
general 
practice 
compared to 
heart failure 
clinics 
189 72.5 European 
Society of 
Cardiology 
2008 
GAI GAI at two 
time-points 
GP GAI baseline = 
95% 
GP GAI1year = 
92% 
HF Clinic GAI 
baseline = 94.65% 
HF Clinic GAI1year 
= 91.1% 
High 
  36 
Study author, 
country, year 
Study design Study aim Sample 
number 
Mean 
age 
(years) 
Guideline 
Assessed 
Assessme
nt Tool 
Equation / 
Modifications 
Main outcomes of 
tool 
Quality 
Ho, 
Australia 
2014 (24) 
Retrospective, 
observational, 
single centre 
study, in 
ambulatory 
care 
Assess 
guideline 
adherence in 
heart failure 
patients with 
multiple 
comorbidities 
255 81.0 Australian 
guidelines 
2009 and 
2012 
Individual 
Reconcile
d 
Evidence-
based 
Recomme
ndations 
Reconciled list 
of evidence-
based 
recommendati
ons 
individualised 
specifically for 
each patient 
Full evidence-
based prescription 
= 93.7% 
Therapeutic goals 
achieved = 88.7% 
Lifestyle 
modifications = 
64% 
High 
  
  37 
Study author, 
country, year 
Study design Study aim Sample 
number 
Mean 
age 
(years) 
Guideline 
Assessed 
Assessme
nt Tool 
Equation / 
Modifications 
Main outcomes of 
tool 
Quality 
Hirt, 
Germany 
2016 (27) 
Three-stage 
study in 
primary care 
units 
Assessment of 
guideline 
adherence in 
general 
practice units 
206 76.7 European 
Society of 
Cardiology 
2012 
GAI Consider 
contraindicatio
ns, target dose 
and prescriber 
concerns 
Contraindication 
based GAI = 56% 
Target dose based 
GAI = 3% 
Good 
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Study author, 
country, year 
Study design Study aim Sample 
number 
Mean 
age 
(years) 
Guideline 
Assessed 
Assessme
nt Tool 
Equation / 
Modifications 
Main outcomes of 
tool 
Quality 
Deticek, 
Slovenia 
2016 (26) 
Prospective, 
single-centre 
study in a 
hospital 
Assessment of 
therapy 
modifications 
in inpatients 
198 77.0 European 
Society of 
Cardiology 
2012 
GAI Consider target 
dose and 
contraindicatio
ns 
GAI-123 = 90% 
GAI-3 = 14% 
mGAI-3 = 7.1% 
GAI-5 = 2.5% 
High 
 
Abbreviations: GAI: Guideline Adherence Index; mGAI: modified Guideline Adherence Index; MRA: mineralocorticoid receptor antagonist; 
RASi: renin-angiotensin system inhibitor. 
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Figure 1. Flow diagram of the systematic review search strategy.   
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Figure 2.  Heart failure patients prescribed >50% of the recommended target dose of (i) beta-blockers and (ii) renin angiotensin system 
inhibitors. 
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Figure 3.   
 
Clinical associates of High Guideline Adherence Index based on data from two study populations (Bosch(28) and Frankenstein (21)) using 
multivariate Cox regression analysis. I2 static = 73.1% p-value <0.001.  
Abbreviations: HF: heart failure; LCL: lower confidence level; MDRD: modified diet for renal disease; NYHA: New York Heart Association; 
OR: odds ratio; UCL: upper confidence level.  
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Figure 4. Meta-analysis of the association between Guideline Adherence Index and mortality.  
Cochran’s Q = 3.8; p-value = 0.924. The following Guideline Adherence Index (GAI) parameters were seen to be associated with mortality risk 
reduction: (a) GAI-3 Medium compared to GAI-3 poor; (b) GAI-3 High compared to GAI-3 low; (c) GAI-5 Medium compared to GAI-5 poor; 
(d) GAI-5 High compared to GAI-5 low; (e) high dose of ACE inhibitor/angiotensin receptor blocker; (f) GAI per 10% increase; (g) GAI-3; (h) 
improvement in GAI over one year; (i) improvement in target dose GAI over one year; (j) GAI-123 compared to GAI-0. Results (a) – (e) based 
on HFrEF cohort, n = 641.  
Definitions: GAI-0: No heart failure recommended medication prescribed; GAI-123: prescription of any one of the top three heart failure 
recommended agents; GAI-3: prescription of all the top three recommended heart failure medications; GAI-5: prescription of all five heart failure 
recommended medications. 
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Supplemetal material
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Supplemental Material Table S1:   
The components of clinical care considered by each tool. 
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A
n
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 o
th
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atien
t 
related
 facto
r 
Guideline Adherence Index studies   ● ● ● ● ● ● ● ● ● ● ● 
1 Komajda 2005   ● ● ● ● ● ●      
2 Klimm 2008   ● ● ● ●   ● ●    
3 Stork 2008   ● ● ● ● ● ● ●     
4 Bosch 2010   ● ● ● ●   ●     
5 Frankenstein 2010   ● ● ● ●        
6 Oertle 2010   ● ● ● ●   ●   ● ● 
7 Zugck 2012   ● ● ● ●   ●     
8 Oliveira 2013   ● ● ● ● ● ● ●    ● 
9 Luttick 2014   ● ● ● ● ● ●      
10 Poelzl 2014   ● ● ● ●   ● ●    
11 Yoo 2014   ● ● ● ●        
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12 Deticek 2016    ● ● ● ● ●   ●   
13 Hirt 2016   ● ● ● ●      ●  
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Non Guideline Adherence Index 
studies 
● ● ● ● ● ● ● ● ● ● ● ●  
14 Popescu 2008 ●  ● ●          
15 Visca 2013  ● ● ● ●    ●     
16 Ho 2014 ●   ● ● ● ● ●  ● ● ●  
 
Abbreviations: GP: general practitioner; IRER: Individualized Reconciled Evidence-based Recommendations; RASi: renin-angiotensin 
system inhibitor. 
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Supplemental Material Table S2  
Drug utilisation rates compared to Guideline Adherence Index for principle heart failure medications. 
 
 
Abbreviations: DUR: drug utilisation rate; GAI: Guideline Adherence Index.  
* Klimm et al. used a Modified Guideline Adherence Index adjusted to patient contraindications and target dose.  
 
Study 
Renin angiotensin systems 
inhibitors (%) 
Beta-blockers (%) 
Mineralocorticoid receptor 
antagonists (%) 
DUR GAI DUR GAI DUR GAI 
Komajda 2005 69.0 85.4 53.0 58.0 28.0 36.0 
Klimm 2008* 80.0 49.0 75.0 46.0 57.0 - 
Bosch 2010 61.3 58.3 54.6 47.0 24.9 31.0 
Oliveira 2013 68.8 73.5 54.1 60.4 49.2 57.1 
Mean 69.8 66.6 59.3 52.9 39.8 41.4 
